Drug Insights

Is Fosdenopterin approved by the FDA?

10 July 2024
3 min read

Fosdenopterin, marketed under the brand name Nulibry, is a medication used to reduce the risk of death in children suffering from molybdenum cofactor deficiency (MoCD) Type A. Fosdenopterin (Nulibry) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021. This approval marked a significant milestone, providing a vital treatment option for a previously untreatable and fatal condition.

Uses and Administration

Uses:

  • Fosdenopterin is used specifically to reduce the risk of mortality in children with MoCD Type A.

Administration:

  • The medication is administered via an intravenous infusion. The dosage is determined based on the patient's weight and gestational age. The infusion is typically given once daily, with adjustments made as the child grows.

Precautions and Considerations

Before Using Fosdenopterin:

  • A genetic test is required to confirm the diagnosis of MoCD Type A before starting treatment. In some cases, treatment may begin before the test results are available, but it will be discontinued if the diagnosis is not confirmed.

Potential Side Effects:

  • Serious Side Effects: Fever, severe or ongoing vomiting or diarrhea, bruising, swelling, discomfort around the catheter site, cough with mucus, trouble breathing, seizures, and signs of ear infection.
  • Common Side Effects: Catheter or IV line issues, fever, vomiting, diarrhea, and cold symptoms such as stuffy nose, sneezing, and cough.

Parents and caregivers should report any side effects to their healthcare provider or directly to the FDA at 1-800-FDA-1088.

Interactions and Storage

Drug Interactions:

  • Fosdenopterin may interact with other medications, including over-the-counter drugs, vitamins, and herbal products. It is crucial to inform the healthcare provider of all medications the child is taking.

Storage:

  • Unmixed fosdenopterin should be stored in a freezer, protected from light, and allowed to reach room temperature before mixing with the diluent for injection. The mixed medication can be stored in the refrigerator or at room temperature but must be used within four hours of preparation.

Dosage Information

Pediatric Dosage:

  • For preterm neonates (gestational age < 37 weeks):
    • Initial dose: 0.4 mg/kg IV once a day
    • At one month: 0.7 mg/kg IV once a day
    • At three months: 0.9 mg/kg IV once a day
  • For term neonates (gestational age ≥ 37 weeks):
    • Initial dose: 0.55 mg/kg IV once a day
    • At one month: 0.75 mg/kg IV once a day
    • At three months: 0.9 mg/kg IV once a day
  • For patients 1 year or older:
    • 0.9 mg/kg IV once a day

Conclusion

This medication provides a critical option for managing this severe genetic disorder, significantly reducing the risk of mortality. However, its administration requires careful monitoring and adherence to prescribed dosages and storage guidelines.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 10
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 10
10 July 2024
Jul 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Is Melphalan flufenamide approved by the FDA?
Drug Insights
3 min read
Is Melphalan flufenamide approved by the FDA?
10 July 2024
Melphalan flufenamide (Pepaxto) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021.
Read →
Immorna Biotherapeutics' JCXH-211 Receives FDA IND Approval for Phase 1/2 Solid Tumor Trial
Latest Hotspot
3 min read
Immorna Biotherapeutics' JCXH-211 Receives FDA IND Approval for Phase 1/2 Solid Tumor Trial
10 July 2024
Immorna Biotherapeutics Gets U.S. FDA IND Approval for JCXH-211 IV Phase 1/2 Trial Alone and with Checkpoint Inhibitor in Advanced Solid Tumor Patients.
Read →
Is Casimersen approved by the FDA?
Drug Insights
3 min read
Is Casimersen approved by the FDA?
10 July 2024
Casimersen was approved by the U.S. Food and Drug Administration (FDA) on February 25, 2021.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.